Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, announced the closing of a $30 million senior secured term loan agreement with Radius Health, Inc. ("Radius Health"). The financing was provided to Radius Health from both Oxford and Solar Capital Ltd. ("Solar Capital"). Proceeds of the loan will be used for working capital and to advance the development of Radius Health's lead candidate, abaloparatide, along with other products.

"Oxford is pleased, once again, to provide financing to Radius Health," said Christopher A. Herr, managing director for Oxford Finance. "We continue to be impressed with the company's extensive pipeline of promising programs and its management team, which has a great deal of experience in drug development and commercialization."

"We are happy to lead this new financing, which allows Radius Health to continue advancing their strong product pipeline," said Anthony Storino, head of healthcare venture lending at Solar Capital. "We look forward to supporting the company's continued progress in the therapeutics space."

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide.

Solar Capital Ltd. is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940.